Chimeric antigen receptor-T cell (CAR-T) therapy has been studied intensively these years and is considered a promising cancer treatment. So far, Food and Drug Administration has approved 2 CAR-T cell therapy for patients with refractory leukemia and the result is positive. However, CAR-T cell therapy is still facing several challenges, including antigen escape, which will diminish the efficacy of treatment and lead to relapse. This review investigates the potential of cancer stem cell (CSC), a small group of cancer cells that contribute to tumorigenesis, metastasis, therapy resistance and relapse, as the target of CAR-T cell therapy, focusing on representative CSC surface markers: CD123, CD133 and CD44. Evidence indicates that CAR-T cell therapy directed by CSC surface markers is effective and feasible. Therefore, CSC targeted CAR-T cell therapy is a prospective treatment for cancer.
TMOD-01. THE ROLE OF PERSISTENCE, PROLIFERATION, AND TUMOR CELL KILLING EFFICIENCY IN DETERMINING RESPONSE TO CAR T-CELL THERAPY IN GLIOBLASTOMA: A MATHEMATICAL MODEL AND ANALYSIS